Navigation Links
Vaccine Pipeline Database: 1-Year Subscription
Date:10/6/2011

NEW YORK, Oct. 6, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Vaccine Pipeline Database: 1-Year Subscription

http://www.reportlinker.com/p0652031/Vaccine-Pipeline-Database-1-Year-Subscription.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Product description

Subscription to La Merie's proprietary Vaccine Pipeline Database provides online access to more than 1,200 project entries for prophylactic and therapeutic vaccines on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of vaccines is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. The projects can be segmented into Territories, Therapeutic Areas and R&D Phases. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase, product category or company name. Sample screenshots illustrate the database.

Purchase of the subscription provides a 1-year online access to the data of the Antibody Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.

Benefits from the Antibody Pipeline Database:

-New database (since 2008) with no historical burden

-Intuitive use

-Designed for structured searches

-Focused on targets, therapeutic areas and R&D phases

-Ideal for competitor analysis (companies, targets, product categories)

-Cost-effective and rapid solution for benchmarking

-Identification of licensing candidates

Project listing in a tabular format:

-Drug Codes

-Target / Mechanism of Action

-Class of Compound

-Product Category

-Company

-Territory

-Therapeutic Area

-Indication

-R&D Phase

Therapeutic Areas:

Cardiovascular & blood

Dermatology

Gastrointestinal

Genitourinary, renal & gynecology

Infectious & toxicology

Metabolism & endocrine

Neurology & psychiatry

Oncology

Ophthalmology & otorhinolaryngology

Orthopedics, dental, anesthesia & surgery

Pulmonary & respiratory

Rheumatoid & autoimmune

Examples of Predefined Targets of the Scroll Down Menu:

Hepatitis Vaccines

Influenza Vaccines

Herpes Virus Vaccines

Staphylococcal Aureus Vaccines

Streptococcal Vaccines

Pseudomonas Aeruginosa Vaccines

Cytomegalovirus (CMV) Vaccines

Tuberculosis Vaccines

Anthrax Vaccines

Respiratory Syncytial Virus (RSV) Vaccines

Human Papilloma Virus (HPV) Vaccines

Malaria Vaccines

Dengue Virus Vaccines

Human Immunodeficiency Virus (HIV) Vaccines

Therapeutic Cancer Vaccines

To order this report:

Drug and Medication Industry: Vaccine Pipeline Database: 1-Year Subscription

Drug and Medication Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
2. Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies
3. Synthetic Genomics Vaccines, Inc. Hires Vaccine Executive Sammy J. Farah as President
4. Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines Potential to Help Ensure Nations Food Supply Safety
5. Nations Pharmacists Ready to Administer Seasonal Flu Vaccines
6. GlycoVaxyns Staphylococcus aureus Bioconjugate Vaccine Candidate Protects Mice Against Invasive S. aureus Infection
7. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
8. Initial Trial of Sanarias Malaria Vaccine Yields Positive Results
9. Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing
10. Anthem Blue Cross Kicks Off Statewide Series Of Free Whooping Cough Vaccine Clinics In Watts On Saturday
11. Pevion Grants CSL Option Right to its Therapeutic Candida Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
Breaking Medicine Technology:
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/21/2017)... , ... April 21, 2017 , ... An April 10 ... a pair of ancient teeth, which reveal a great deal about prehistoric ice-age dental ... sharp stone may have been used to remove decayed dental matter, and that teeth ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. ... osteoma is a benign bony lump located on the forehead usually attributed to a ... with sight and pain. Dr. Shah has discovered an approach that is minimally invasive. ...
(Date:4/21/2017)... ... 21, 2017 , ... Dudnyk has announced the launch of its new brand ... full potential of specialty and orphan brands can only be achieved when the needs ... Unifying Effect is at the heart of a true partnership between our agency and ...
(Date:4/21/2017)... ... , ... The Hong Kong Polytechnic University (PolyU) launched today the University Research ... in Hong Kong to support teaching, learning and research. It is also the largest ... in Hong Kong. , With an area of 620 square metres and more ...
Breaking Medicine News(10 mins):